Table 2.
Relative expression of T cell-associated molecules from astrocytes under the inflammatory media treatment at the mRNA level
| con (Ct value) | con | 6 h | 12 h | 24 h | 48 h | |
|---|---|---|---|---|---|---|
| IL-17 | 40·00 | 1·00 | 28·31 ± 4·05 | 160·53 ± 25·51 | 4·09 ± 1·47 | 10·36 ± 1·62 |
| IL-17F | 33·19 | 1·00 | 25·16 ± 4·44 | 5·05 ± 1·69 | 1·52 ± 0·30 | 1·65 ± 0·42 |
| IL-6 | 26·2 | 1·00 | 6·38 ± 1·95 | 0·96 ± 0·86 | 0·38 ± 0·19 | 0·42 ± 0·26 |
| IFN-γ | 40·00 | 1·00 | 0·66 ± 0·27 | 97·46 ± 16·24 | 4·24 ± 2·57 | 0·69 ± 0·37 |
| IL-12p40 | 32·93 | 1·00 | 0·40 ± 0·20 | 0·56 ± 0·16 | 0·53 ± 0·08 | 0·95 ± 0·33 |
| IL-23p19 | 28·1 | 1·00 | 2·50 ± 1·30 | 1·01 ± 0·53 | 0·79 ± 0·34 | 0·78 ± 0·48 |
| ROR-γt | 29·92 | 1·00 | 0·38 ± 0·05 | 0·20 ± 0·19 | 0·59 ± 0·12 | 1·58 ± 0·35 |
| GATA-3 | 30·53 | 1·00 | 3·98 ± 1·45 | 0·82 ± 0·30 | 0·38 ± 0·18 | 0·78 ± 0·38 |
| T-bet | 31·46 | 1·00 | 0·24 ± 0·05 | 5·53 ± 1·65 | 1·14 ± 0·40 | 0·62 ± 0·29 |
| FoxP3 | 32·93 | 1·00 | 0·39 ± 0·16 | 1·27 ± 0·33 | 0·68 ± 0·26 | 0·90 ± 0·31 |
| TGF-β | 21·91 | 1·00 | 0·60 ± 0·24 | 0·78 ± 0·24 | 0·56 ± 0·21 | 0·83 ± 0·36 |
| NGF | 26·93 | 1·00 | 1·19 ± 0·43 | 0·89 ± 0·32 | 0·76 ± 0·22 | 1·18 ± 0·41 |
| CNTF | 22·93 | 1·00 | 1·11 ± 0·44 | 0·68 ± 0·19 | 1·11 ± 0·51 | 1·34 ± 0·58 |
Primary astrocytes were treated with the cell-free supernatants of peripheral blood mononuclear cells (PBMC) pretreated with phorbol mysristate acetate (PMA) and ionomycin for 6 h. The relative expression of cytokines and transcription factors was measured by quantitative reverse transcription–polymerase chain reaction (qRT–PCR) after 6, 12, 24 and 48 h. Genes expression at least a 2-fold change was recognized as being significantly altered and in bold type. IL: interleukin; IFN: interferon; ROR-γt: retinoic acid receptor-related orphan receptor gammat; GATA-3: GATA-binding protein 3; FoxP3: forkhead box protein 3; TGF: transforming growth factor; con: unstimulated, unstimulated astrocytes; NGF: nerve growth factor; CNTF: ciliary neurotrophic factor.